Natrecor Labeling Revised To Include Expanded Mortality Analysis
Executive Summary
Johnson & Johnson/Scios' Natrecor (nesiritide) labeling has been revised to include an expanded analysis of the mortality rates seen in pivotal trials of the congestive heart failure agent
You may also be interested in...
FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article
The ongoing debate surrounding the safety of Scios' congestive heart failure therapy Natrecor (nesiritide) suggests that FDA should not approve drugs based only on surrogate endpoints, an article published in the July/August 2006 issue of Health Affairs argues
FDA Approval Shouldn’t Be Based On Surrogate Endpoints – Natrecor Article
The ongoing debate surrounding the safety of Scios' congestive heart failure therapy Natrecor (nesiritide) suggests that FDA should not approve drugs based only on surrogate endpoints, an article published in the July/August 2006 issue of Health Affairs argues
Medicare Outpatient Coverage Of Natrecor Could Be Limited To Clinical Trials
The Centers for Medicare & Medicaid Services' national coverage determination for Johnson & Johnson's Natrecor (nesiritide) will be one of the first opportunities for the agency to implement its "coverage with evidence development" policy